scholarly journals Health State Utilities and Quality of Life in Patients with Hepatitis B

2012 ◽  
Vol 26 (7) ◽  
pp. 445-451 ◽  
Author(s):  
Gloria Woo ◽  
George Tomlinson ◽  
Colina Yim ◽  
Les Lilly ◽  
George Therapondos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Standard Gamble ◽  
Antiviral Treatment ◽  
Decompensated Cirrhosis ◽  
Health State ◽  
Disease States ◽  
Compensated Cirrhosis ◽  
Health State Utilities

BACKGROUND: The effect of chronic hepatitis B (CHB) infection on health-related quality of life (HRQoL) and health state utilities has not been well characterized.OBJECTIVE: To measure utility scores and HRQoL across disease states associated with CHB infection.METHODS: Patients attending four tertiary care clinics for CHB were approached between July 2007 and March 2009. Respondents completed version 2 of the Short-Form 36 Health Survey, the EQ5D, a visual analogue scale, the Health Utilities Index Mark 3, standard gamble, and demographics and risk factor surveys in English, Cantonese or Mandarin. Charts were reviewed to determine disease stage and comorbidities.RESULTS: A total of 433 patients were studied: 294 had no cirrhosis; 79 had compensated cirrhosis; seven had decompensated cirrhosis; 23 had hepatocellular carcinoma; and 30 had received a liver transplant. The mean standard gamble utilities for these disease states were 0.89, 0.87, 0.82, 0.84 and 0.86, respectively. HRQoL scores in noncirrhotic patients were similar to those of the general population. Scores of patients with compensated cirrhosis were not significantly lower; however, patients with decompensated cirrhosis and hepatocellular carcinoma had significantly lower HRQoL scores compared with noncirrhotic patients (P<0.05). Similar scores were observed among patients on and off oral antiviral treatment. Post-liver transplant patients had a higher HRQoL than patients with decompensated cirrhosis. Age, number of comorbidities and relationship status were significantly associated with HRQoL scores.CONCLUSIONS: HRQoL in CHB patients is only impaired in the later stages of liver disease. Neither CHB infection nor antiviral treatment is associated with a lower quality of life.

VP133 Patient-Reported Health State Utilities In Neuroendocrine Tumours

2017 ◽  
Vol 33 (S1) ◽  
pp. 210-210
Author(s):  
Yang Meng ◽  
Grant McCarthy ◽  
Anthony Berthon ◽  
Jerome Dinet
Keyword(s):  
Quality Of Life ◽  
Progressive Disease ◽  
Neuroendocrine Tumours ◽  
Disease State ◽  
Health State ◽  
Utility Values ◽  
Patient Reported ◽  
Health State Utilities ◽  
Reported Health

INTRODUCTION:Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most often found in the gastrointestinal system or the pancreas. However, patient-reported health state utilities based on clinical trials have not been previously reported in this disease area.METHODS:The CLARINET study collected the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 data from patients in both stable and progressive disease states, although data for the latter were only available during the early stage of progression due to trial design. Using published algorithms, data were mapped to EQ-5D utility values. Random-effects generalized least squares models were used to investigate the impacts of progression status, tumour site and other patient characteristics on mapped utility values.RESULTS:In total, 1,053 observations from 204 patients were mapped to EuroQol (EQ-5D) utilities using the McKenzie mapping algorithm. The final random-effects model included age, gender, baseline utility and progression status as covariates; it was not feasible to investigate time-to-death utility due to a limited number of death in the CLARINET study. Tumour location (midgut versus pancreas) does not seem to affect utility. However, the difference in utilities based on progression status is statistically significant (p<.05) in the base case analysis, and the estimated utilities for stable and progressive disease are .776 and .726, respectively. Furthermore, scenario analyses showed that utility for progressive disease is numerically lower than for stable disease, but this may not be statistically significant in some scenarios.CONCLUSIONS:Patients with GEP-NETs experience worse utility values in the progressive disease state compared to the stable disease state, based on patient-reported health-related quality of life (HRQL) data from the CLARINET study. The decline of utility in the progressive disease state may be underestimated because progressive HRQL data were only collected shortly after the progression event in the trial. The estimated trial-based utilities can be used in future economic evaluations for GEP-NET treatments and to provide more insights to physicians on patient-reported quality of life outcomes in GEP-NETs.

scholarly journals Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study

2021 ◽  
Author(s):  
Martina Treskova ◽  
Stefan Scholz ◽  
Alexander Kuhlmann ◽  
Jörg Mahlich ◽  
Matthias Stoll
Keyword(s):  
Quality Of Life ◽  
Patient Characteristics ◽  
Hiv And Aids ◽  
People Living With Hiv ◽  
Health State ◽  
Utility Values ◽  
Health State Utilities ◽  
Living With Hiv ◽  
Eq Vas

AbstractHIV has become a chronic disease since widespread of combined antiretroviral therapy (cART). Understanding the influence of therapeutic and preventive interventions on health-related quality of life (HRQoL) of people living with HIV and AIDS (PLWHA) is important. Information about health state utilities and HRQoL in PLWHA after the introduction of cART is limited, especially in Germany. The study aims to estimate and describe health state utilities and HRQoL in PLWHA in Germany and explore the effects of patient characteristics, clinical and treatment factors. Utilities and HRQoL in PLWHA in Germany were measured with the generic EQ-5D-3L questionnaire. Health state utilities were calculated based on the EQ-5D descriptive system using the German EQ-5D-3L time trade-off (TTO) value set. HRQoL was calculated based on the EQ visual analogue scale (EQ-VAS). Extensive descriptive analyses were performed to represent utility values for different groups of the patients. Generalized linear models (GLMs) with beta-inflated distributions were used to determine patient characteristics and clinical factors that influence TTO utilities and VAS scores. 1056 PLWHA completed the EQ-5D-3L questionnaires at the beginning of the study. The mean TTO utility value is 0.912 (SD ± 0.154), and the mean VAS HRQoL is 84.32 (SD ± 18.55). “Anxiety/depression” and “pain/physical discomfort” are the most affected dimensions. A longer period of living with HIV, a lower CD4-cell count, having symptomatic HIV or AIDS and an increased number of changes in therapy are associated with decreased utilities and a lower probability of having HRQoL of perfect health. No significant effect of duration of regimen was found. Depression significantly decreases TTO utility values. Higher education, full-time employment and female gender are associated with higher utilities. The resulted EQ-VAS values for PLWHA in Germany are comparable with EQ-VAS estimates for the general population. The obtained estimates can be used as inputs for health economic evaluations of HIV-interventions. Addressing anxiety and depression may reduce the quality of life impairment in PLWHA. Impact of comorbidities needs further investigation.

scholarly journals Quality of Life and Health State Utilities in Bladder Cancer

2021 ◽  
pp. 1-16
Author(s):  
Angela B. Smith ◽  
Sean McCabe ◽  
Allison M. Deal ◽  
Amy Guo ◽  
Kathryn H. Gessner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Metastatic Disease ◽  
Cost Effective ◽  
Health State ◽  
Financial Toxicity ◽  
Metastatic Bladder Cancer ◽  
Health State Utilities ◽  
Muscle Invasive

BACKGROUND: Bladder cancer treatments may variably impact health-related quality of life (QOL). OBJECTIVE: To characterize the quality of life of patients with bladder cancer at various time points across the continuum of bladder cancer care from non-muscle-invasive disease to metastatic bladder cancer and develop utility scores to inform cost-effective analyses. METHODS: We performed a cross-sectional survey of bladder cancer patients in the Bladder Cancer Advocacy Network Patient Survey Network. Participants were classified into mutually exclusive health states based upon non-muscle invasive (NMIBC), muscle-invasive (MIBC), or metastatic bladder cancer and completed surveys of generic cancer and bladder cancer-specific quality of life, financial toxicity, and work impairment. We constructed generalized linear mixed models to identify patient, clinical, and treatment factors associated with quality of life over time and derived health state utilities. RESULTS: Among 911 self-identified patients with bladder cancer, overall QOL scores and function domains were worse among those with advanced cancer. Financial toxicity was similar among non-metastatic disease states. Work and activity impairment increased with advancing disease (13%and 12%among non-recurrent NMIBC to 63%and 31%for metastatic disease respectively; p <  0.01). On multivariable analysis, bowel-related QOL was diminished among patients with MIBC, with urinary symptoms and physical function most diminished among patients with metastatic disease. Patients with metastatic and MIBC experienced worse emotional functioning (p = 0.04; p = 0.048). Health state utilities were calculated, highest among those with non-recurrent NMIBC and lowest among those with metastatic disease. CONCLUSION: Generic and bladder cancer-specific QOL diminishes with advancing disease. Health state utility estimates derived from this study can inform shared decision making with patients and may be used to inform future cost-effective analyses.

The impact of depression is unevenly distributed in the population

2005 ◽  
Vol 20 (3) ◽  
pp. 205-212 ◽  
Author(s):  
Dag Isacson ◽  
Kerstin Bingefors ◽  
Lars von Knorring
Keyword(s):  
Quality Of Life ◽  
General Population ◽  
Burden Of Disease ◽  
Health State ◽  
Medical Disorders ◽  
Sf 36 ◽  
Depressed Group ◽  
Health State Utilities ◽  
The Impact

AbstractAimThe aim of this study was to evaluate the impact of depression on quality of life in the general population by studying its effects on i) health-related quality of life (HRQoL), ii) health state utilities, and iii) the burden of disease in the population according to age, sex, marital status, education, economy and employment.MethodsCross-sectional survey in the County of Uppsala, Sweden. A statistical sample of the general population aged 20–64 years (N = 4506) was used. Information on current state of depression was obtained by self-report. HRQoL was measured using Short Form 36 (SF-36). The time trade-off (TTO) method was used to measure health state utilities. The decrease of total health state utilities associated with depression in the population was used as a measure of burden of disease.ResultsDepression was reported by 4.0% of the population. Those with depression scored significantly lower (P < 0.001) than those without on all eight of the SF-36 domains. The depressed group also rated their health state utilities significantly lower than the others: 0.796 versus 0.933 (P < 0.001). In the multivariate analysis of decrease in utilities with various medical disorders, depression was associated with the greatest decrease (–0.090, P < 0.001). Persons with depression accounted for 10.9% of the total decrease in utilities in the whole population, but this proportion varied according to the specific subgroup. For example, 16.4% and 8.6% of the total burden of disease was linked to depression among single and married people, respectively. The corresponding figures for those with the lowest and highest incomes were 15.0% and 7.9%, respectively. Among the unemployed, persons reporting depression accounted for 15.3% of the decrease in utilities in contrast to 4.9% among the employed.ConclusionsDepression has a strong impact on the quality of life and total disability in the general population. Further, the impact of depression is unevenly distributed in the population.

Health-State Utilities and Quality of Life in Hepatitis C Patients

2003 ◽  
Vol 98 (3) ◽  
pp. 630-638 ◽  
Author(s):  
Christopher A.K.Y. Chong ◽  
Anar Gulamhussein ◽  
E.Jenny Heathcote ◽  
Les Lilly ◽  
Morris Sherman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hepatitis C ◽  
Health State ◽  
Health State Utilities

scholarly journals Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

2021 ◽  
Author(s):  
Karissa M. Johnston ◽  
Gilbert L’Italien ◽  
Evan Popoff ◽  
Lauren Powell ◽  
Robert Croop ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Health State ◽  
Health State Utilities
Sign in / Sign up

Export Citation Format

Share Document